Tradipitant is a selective human substance P/neurokinin-1 receptor antagonist approved for the prevention of vomiting induced by motion in adults.

Analysts raise price targets for Vanda Pharmaceuticals after FDA approved a motion sickness drug, citing growth potential.

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment ...

Jefferies analysts envision a steady launch curve that could ultimately drive meaningful sales from people who are ...

Don’t tell Neil Armstrong, but giant leaps for mankind may leave astronauts feeling a little queasy. In a new experiment, aerospace engineers at the University of Colorado Boulder will work with ...

The US Food and Drug Administration (FDA) has approved Vanda Pharmaceuticals’ Nereus (tradipitant) for the prevention of ...

Motion sickness sufferers will know all too well how feelings of nausea can linger even after movement has stopped. But researchers in China may have found a way to speed up recovery — listen to happy ...

My first experience with motion sickness was as a college student, standing on the back of a marine research vessel looking at interesting things dredged from the seafloor off the California coast. It ...

A new study explored why the severity of motion sickness varies from person to person by investigating sources of cybersickness during VR use. A new study led by Head of the Rokers Vision Laboratory ...

Vanda Pharmaceuticals said on Tuesday its drug for the prevention of motion-induced vomiting was approved by the U.S. health ...